Apica Sellers Representative, LLC v. Abbott Laboratories

Background

Apica Sellers Representative, LLC alleged that Abbott Laboratories failed to pay at least $40 million in overdue milestone payments under an Equity Purchase Agreement. The agreement originally involved Apica Cardiovascular Limited and Thoratec Switzerland GmbH. It named Seroba Kernel Life Sciences Fund II Limited Partnership as the representative for the former shareholders of Apica Cardiovascular Limited in post-closing disputes. Seroba later resigned and appointed Apica Sellers Representative, LLC as its replacement. The opinion states that Apica’s sole members are Seroba and TriVentures Fund II LP.

Abbott moved for summary judgment, arguing that Apica lacked standing because Apica was not a party to the agreement and could not recover or financially benefit from the payments. In response, Apica argued that its appointment as the sellers’ representative gave it authority to enforce the former shareholders’ rights. Apica also asked to add Seroba and TriVentures as plaintiffs to address any standing deficiency. Abbott opposed the request, arguing that the deadline for amending the pleadings had passed, that Apica lacked standing, and that adding parties at that stage would cause prejudice and delay.

Court’s Analysis

The court treated Apica’s motion for joinder as a motion for leave to amend because adding parties would require an amended complaint. Rule 15 generally allows amendment with the court’s permission, while Rule 21 permits adding parties at any time on just terms. Because the court’s scheduling order had set an August 25, 2023 deadline for amended pleadings, the court also applied Rule 16’s requirement that the party show good cause to modify the deadline.

The court found that Apica had acted diligently. Although Apica missed the amendment deadline, Abbott did not raise the standing issue until significantly later. Apica attempted to resolve Abbott’s objection without motion practice and filed its motion 21 days after Abbott filed its summary-judgment motion. The court also noted that the parties had treated Seroba and TriVentures as involved in the litigation during discovery, including by allowing Abbott to depose their principals.

The court found no undue prejudice to Abbott. Abbott had already deposed corporate managers for Seroba and TriVentures, had not reported discovery disputes involving them, and had not identified additional burdens or discovery that would be required. The court further concluded that judicial efficiency favored amendment because adding the parties would not change Apica’s claims and would allow the dispute to proceed toward adjudication on the merits.

Disposition

The court GRANTED Apica’s motion to amend its complaint and directed Apica to file an amended complaint by December 19, 2025. This opinion did not rule on Abbott’s summary-judgment motion, decide whether Apica had standing, or resolve whether Abbott owed the claimed milestone payments.